312 related articles for article (PubMed ID: 28164761)
1. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
[TBL] [Abstract][Full Text] [Related]
3. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
[TBL] [Abstract][Full Text] [Related]
6. Progress in developing MNK inhibitors.
Jin X; Yu R; Wang X; Proud CG; Jiang T
Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
8. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
[TBL] [Abstract][Full Text] [Related]
9. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
[TBL] [Abstract][Full Text] [Related]
11. Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
Cherian J; Nacro K; Poh ZY; Guo S; Jeyaraj DA; Wong YX; Ho M; Yang HY; Joy JK; Kwek ZP; Liu B; Wee JL; Ong EH; Choong ML; Poulsen A; Lee MA; Pendharkar V; Ding LJ; Manoharan V; Chew YS; Sangthongpitag K; Lim S; Ong ST; Hill J; Keller TH
J Med Chem; 2016 Apr; 59(7):3063-78. PubMed ID: 27011159
[TBL] [Abstract][Full Text] [Related]
12. Mnk inhibitors: a patent review.
Abdelaziz AM; Yu M; Wang S
Pharm Pat Anal; 2021 Jan; 10(1):25-35. PubMed ID: 33441033
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
[TBL] [Abstract][Full Text] [Related]
14. BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.
Santag S; Siegel F; Wengner AM; Lange C; Bömer U; Eis K; Pühler F; Lienau P; Bergemann L; Michels M; von Nussbaum F; Mumberg D; Petersen K
Cancer Lett; 2017 Apr; 390():21-29. PubMed ID: 28043914
[TBL] [Abstract][Full Text] [Related]
15. Update on the Development of MNK Inhibitors as Therapeutic Agents.
Xu W; Kannan S; Verma CS; Nacro K
J Med Chem; 2022 Jan; 65(2):983-1007. PubMed ID: 34533957
[TBL] [Abstract][Full Text] [Related]
16. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
17. Optimization of 4,6-Disubstituted Pyrido[3,2-
Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
20. Dynamical insights of Mnk2 kinase activation by phosphorylation to facilitate inhibitor discovery.
Kumarasiri M; Teo T; Wang S
Future Med Chem; 2015; 7(2):91-102. PubMed ID: 25685999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]